The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
申请人:Huang Taisheng
公开号:US20110224190A1
公开(公告)日:2011-09-15
The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
申请人:Janssen Pharmaceutica NV
公开号:US20170313691A1
公开(公告)日:2017-11-02
The present invention comprises compounds of Formula I.
wherein:
A
1
, A
2
, A
3
, A
4
, A
5
, R
1
, and R
2
are defined in the specification.
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
[EN] THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
申请人:GENENTECH INC
公开号:WO2017058821A1
公开(公告)日:2017-04-06
The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
[EN] 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS<br/>[FR] PURINES 2,6,7,8-SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HDM2
申请人:MERCK SHARP & DOHME
公开号:WO2014120748A1
公开(公告)日:2014-08-07
The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.